===日本臨床検査医学会 機関誌============================================================== Vol. 53 No. 7 2005 ■原著 高濃度領域測定用 Cobas Amplicor HCV Monitor v2.0(ハイレンジ法)の 野 よしみ・・・ 587 免疫毒性の検討 ······································································································川 口 雄 才・・・ 594 メガデータによる性別年齢階級別基準範囲の作成···············································須 賀 万 智・・・ 599 口 桂 司・・・ 609 薬剤起因性血小板減少症の定義と発症メカニズムについて ·······························野 村 昌 作・・・ 617 ヘパリン起因性血小板減少症−病因，検査，治療−···········································松 尾 武 文・・・ 622 チクロピジンによる血栓性血小板減少性紫斑病の臨床と検査 ···························八 木 秀 男・・・ 630 TTP 迅速診断を目的とした新規 ADAMTS13 測定法の開発と応用····················小 亀 浩 市・・・ 639 EDTA 依存性偽性血小板減少症の臨床と検査·······················································西 郷 勝 康・・・ 646 希釈性血小板減少の検査と治療 ··············································································石 田 明・・・ 654 付録 : 薬物依存性血小板減少症候補薬物のデータベース··································小宮山 豊・・・ 658 基礎的検討および臨床的有用性について···························································福 全血での LPS 刺激 TNF-α 産生能を用いた塩酸イリノテカンの ■シリーズ：病院検査部が行うコンサルティング業務の実際 富山医科薬科大学病院検査部 検査よろず相談室開設 1 年の経過とその役割···················································山 ■トピックス：薬剤起因性血小板減少症の病態と検査(ITP, HIT, TTP) ■資料 新規保険収載検査項目の解説−体外診断薬に係る保険適応上の 取扱いの見直しについて− ··················································································宮 澤 幸 久・・・ 668 ■日本臨床検査医学会ニュース 日本臨床検査医学会だより ························································································································ 670 ===The Official Journal of Japanese Society of Laboratory Medicine======================= Rinsho Byori Vol. 53 No. 7 2005 ■Original Clinical Significance of Cobas Amplicor HCV Monitor Test v 2.0 for Quantifying a Wide Range of Serum HCV-RNA in Patients with Chronic Hepatitis C········ Yoshimi FUKUNO・・・ 587 Assessment of Immunotoxicity of Irinotecan Determined by the Novel Method, by which Productivity of TNF-α from Whole Blood Stimulated by Lipopolysaccharide ·······················Yusai KAWAGUCHI・・・ 594 Age- and Sex-Specific Reference Intervals for 10 Health Examination Items: Mega-Data from a Japanese Health Service Association ·············································Machi SUKA・・・ 599 ■Sires：Consulting Work performed by the Hospital Laboratory Annual Progress Report of the Laboratory Information and Consulting Work and Its Role in Toyama Medical and Pharmaceutical University Hospital············· Keiji YAMAGUCHI・・・ 609 ■Topics： Definition and Mechanism of Drug-Induced Thrombocytopenia························· Shosaku NOMURA・・・ 617 Heparin-Induced Thrombocytopenia(HIT): Pathogenesis, Laboratory Test, and Treatment ··············································· Takefumi MATSUO・・・ 622 Clinical Features and Laboratory Findings of Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine ············································Hideo YAGI・・・ 630 Development and Application of a New ADAMTS13 Assay for TTP Diagnosis ································································································ Koichi KOKAME・・・ 639 EDTA-Dependent Pseudothrombocytopenia: Clinical Aspects and Laboratory Tests································································ Katsuyasu SAIGO・・・ 646 Examination and Treatment of Dilutional Thrombocytopenia···································· Akaru ISHIDA・・・ 654 Appendix: Putative Drug List of Drug-induced Thrombocytopenia ··················Yutaka KOMIYAMA・・・ 658 ■Report Diagnostic Tests Approved by Ministry of Health and Welfare······························································ 668 ■News JSLM NEWS ·············································································································································· 670
© Copyright 2024 ExpyDoc
